Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.

Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.

Hanekamp D. et al, (2020), Br J Haematol, 190, 891 - 900

Mechanisms of Response and Resistance to AML Therapies.

Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.

Roos-Weil D. et al, (2020), Blood, 136, 585 - 595

A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome.

Bache I. et al, (2020), Blood Cancer J, 10

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M. et al, (2019), Cancer Cell, 36

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D. et al, (2019), Cancer Discov, 9, 796 - 811

Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood

Hanssen L. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 106 - 106

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Labuhn M. et al, (2018), BLOOD, 132

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L. et al, (2018), Nat Med, 24, 1167 - 1177

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Quek L. et al, (2017), BLOOD, 130

Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS

Roberts I. et al, (2017), BLOOD, 130

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF. et al, (2017), Clin Cancer Res, 23, 6430 - 6440

MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY

Craddock C. et al, (2017), HAEMATOLOGICA, 102, 323 - 323

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Quek L. et al, (2016), Blood Adv, 1, 193 - 204

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535

NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE

Quek L. et al, (2016), HAEMATOLOGICA, 101, 213 - 213

Include forthcoming?